• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evaluating the incremental value of new biomarkers with integrated discrimination improvement.评估具有综合判别改善的新生物标志物的增量价值。
Am J Epidemiol. 2011 Aug 1;174(3):364-74. doi: 10.1093/aje/kwr086. Epub 2011 Jun 14.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Assessing the incremental predictive performance of novel biomarkers over standard predictors.评估新型生物标志物相对于标准预测指标的增量预测性能。
Stat Med. 2014 Jul 10;33(15):2577-84. doi: 10.1002/sim.6165. Epub 2014 Apr 9.
4
The power-integrated discriminant improvement: An accurate measure of the incremental predictive value of additional biomarkers.功率综合判别改进:附加生物标志物增量预测价值的准确度量。
Stat Med. 2019 Jun 30;38(14):2589-2604. doi: 10.1002/sim.8135. Epub 2019 Mar 12.
5
Asymptotic distribution of ∆AUC, NRIs, and IDI based on theory of U-statistics.基于U统计量理论的ΔAUC、NRI和IDI的渐近分布。
Stat Med. 2017 Sep 20;36(21):3334-3360. doi: 10.1002/sim.7333. Epub 2017 Jun 19.
6
Net Reclassification Index and Integrated Discrimination Index Are Not Appropriate for Testing Whether a Biomarker Improves Predictive Performance.净重新分类指数和综合判别指数不适用于检验生物标志物是否能改善预测性能。
Toxicol Sci. 2017 Mar 1;156(1):11-13. doi: 10.1093/toxsci/kfw225.
7
A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index.关于新型生物标志物评估的一则注释:不要依赖综合判别改善和净重新分类指数。
Stat Med. 2014 Aug 30;33(19):3405-14. doi: 10.1002/sim.5804. Epub 2013 Apr 2.
8
Inference for reclassification statistics under nested and non-nested models for biomarker evaluation.用于生物标志物评估的嵌套和非嵌套模型下重新分类统计量的推断。
Biomarkers. 2015;20(4):240-52. doi: 10.3109/1354750X.2015.1068854.
9
Interpreting incremental value of markers added to risk prediction models.解读风险预测模型中新增标志物的增量价值。
Am J Epidemiol. 2012 Sep 15;176(6):473-81. doi: 10.1093/aje/kws207. Epub 2012 Aug 8.
10
The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.生物标志物对改良心脏风险指数在预测非心脏手术患者主要不良心脏事件和全因死亡率方面的比较和附加预后价值。
Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD013139. doi: 10.1002/14651858.CD013139.pub2.

引用本文的文献

1
A Novel Depression Risk Prediction Model Using NHANES Data With Mendelian Randomization Validation.一种使用美国国家健康与营养检查调查(NHANES)数据并经孟德尔随机化验证的新型抑郁症风险预测模型。
Brain Behav. 2025 Jul;15(7):e70674. doi: 10.1002/brb3.70674.
2
The association of the metabolic score for insulin resistance and metabolic dysfunction-related steatosis liver disease: a population-based observational study.胰岛素抵抗代谢评分与代谢功能障碍相关脂肪性肝病的关联:一项基于人群的观察性研究。
Eur J Med Res. 2025 Jul 23;30(1):657. doi: 10.1186/s40001-025-02936-2.
3
Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: external validation utilizing data from two cohorts.评估五种非侵入性检测方法对代谢相关脂肪性肝病(MASLD)的诊断效能:利用两个队列的数据进行外部验证
Front Nutr. 2025 May 22;12:1571487. doi: 10.3389/fnut.2025.1571487. eCollection 2025.
4
Improving the Estimation of Prediction Increment Measures in Logistic and Survival Analysis.改进逻辑回归和生存分析中预测增量指标的估计
Cancers (Basel). 2025 Apr 8;17(8):1259. doi: 10.3390/cancers17081259.
5
The Value of TyG-Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD.TyG相关指标在评估代谢相关脂肪性肝病(MASLD)及MASLD显著肝纤维化中的价值
Can J Gastroenterol Hepatol. 2025 Mar 13;2025:5871321. doi: 10.1155/cjgh/5871321. eCollection 2025.
6
A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug Development.一种评估连续生物标志物在药物研发早期阶段预测性的新方法。
Stat Med. 2025 Feb 28;44(5):e70026. doi: 10.1002/sim.70026.
7
Integrating D-Dimer Thresholds into the Revised Caprini Risk Stratification to Predict Deep Vein Thrombosis Risk in Preoperative Knee Osteoarthritis Patients.将D-二聚体阈值纳入修订的Caprini风险分层以预测术前膝关节骨关节炎患者深静脉血栓形成风险
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296241311265. doi: 10.1177/10760296241311265.
8
Comprehensive analysis of psychological symptoms and quality of life in early patients with IBD: a multicenter study from China.炎症性肠病早期患者心理症状与生活质量的综合分析:来自中国的多中心研究。
BMC Psychiatry. 2024 Nov 12;24(1):792. doi: 10.1186/s12888-024-06247-4.
9
Fetal Fraction of Cell-Free DNA in the Prediction of Adverse Pregnancy Outcomes: A Nationwide Retrospective Cohort Study.游离DNA的胎儿分数在不良妊娠结局预测中的作用:一项全国性回顾性队列研究
BJOG. 2025 Feb;132(3):318-325. doi: 10.1111/1471-0528.17978. Epub 2024 Oct 2.
10
Comparing CHADS-VA and CHADS-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort.比较CHADS-VA和CHADS-VASc评分在房颤患者卒中风险分层中的应用:来自芬兰房颤抗凝(FinACAF)回顾性队列的时间趋势分析
Lancet Reg Health Eur. 2024 Jun 10;43:100967. doi: 10.1016/j.lanepe.2024.100967. eCollection 2024 Aug.

本文引用的文献

1
The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women: the Women's Health Initiative Observational Study.绝经后女性中炎症和内皮功能障碍的循环生物标志物对2型糖尿病风险预测的无用性:女性健康倡议观察性研究
Arch Intern Med. 2010 Sep 27;170(17):1557-65. doi: 10.1001/archinternmed.2010.312.
2
Improvement of risk prediction by genomic profiling: reclassification measures versus the area under the receiver operating characteristic curve.基因组分析可改善风险预测:重新分类测量与接收者操作特征曲线下面积。
Am J Epidemiol. 2010 Aug 1;172(3):353-61. doi: 10.1093/aje/kwq122. Epub 2010 Jun 18.
3
Recent advances in evaluating the prognostic value of a marker.评估标志物预后价值的最新进展。
Scand J Clin Lab Invest Suppl. 2010;242:59-62. doi: 10.3109/00365513.2010.493389.
4
Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.30 种生物标志物对 2 个人群队列 10 年心血管风险评估的贡献:MONICA、风险、遗传学、存档和专论(MORGAM)生物标志物项目。
Circulation. 2010 Jun 8;121(22):2388-97. doi: 10.1161/CIRCULATIONAHA.109.901413. Epub 2010 May 24.
5
Biomarkers in peripheral arterial disease patients and near- and longer-term mortality.外周动脉疾病患者的生物标志物与近、长期死亡率。
J Vasc Surg. 2010 Jul;52(1):85-90. doi: 10.1016/j.jvs.2010.02.004. Epub 2010 May 14.
6
Measures to summarize and compare the predictive capacity of markers.总结和比较标志物预测能力的方法。
Int J Biostat. 2009 Oct 1;5(1):Article 27. doi: 10.2202/1557-4679.1188.
7
Combined analyses of 20 common obesity susceptibility variants.20 个常见肥胖易感性变异的联合分析。
Diabetes. 2010 Jul;59(7):1667-73. doi: 10.2337/db09-1042. Epub 2010 Jan 28.
8
Integrated discrimination improvement and probability-sensitive AUC variants.集成判别改进和概率敏感的AUC变体。
Stat Med. 2010 Jan 30;29(2):318-9. doi: 10.1002/sim.3761.
9
Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population.餐后血糖可改善非糖尿病人群中除代谢综合征之外的心血管死亡风险预测。
Diabetes Care. 2009 Sep;32(9):1721-6. doi: 10.2337/dc08-2337. Epub 2009 Jun 5.
10
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.心血管风险新标志物评估标准:美国心脏协会的科学声明
Circulation. 2009 May 5;119(17):2408-16. doi: 10.1161/CIRCULATIONAHA.109.192278. Epub 2009 Apr 13.

评估具有综合判别改善的新生物标志物的增量价值。

Evaluating the incremental value of new biomarkers with integrated discrimination improvement.

机构信息

Department of Biostatistics, School of Public Health, University of Washington, Seattle, USA.

出版信息

Am J Epidemiol. 2011 Aug 1;174(3):364-74. doi: 10.1093/aje/kwr086. Epub 2011 Jun 14.

DOI:10.1093/aje/kwr086
PMID:21673124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3202159/
Abstract

The integrated discrimination improvement (IDI) index is a popular tool for evaluating the capacity of a marker to predict a binary outcome of interest. Recent reports have proposed that the IDI is more sensitive than other metrics for identifying useful predictive markers. In this article, the authors use simulated data sets and theoretical analysis to investigate the statistical properties of the IDI. The authors consider the common situation in which a risk model is fitted to a data set with and without the new, candidate predictor(s). Results demonstrate that the published method of estimating the standard error of an IDI estimate tends to underestimate the error. The z test proposed in the literature for IDI-based testing of a new biomarker is not valid, because the null distribution of the test statistic is not standard normal, even in large samples. If a test for the incremental value of a marker is desired, the authors recommend the test based on the model. For investigators who find the IDI to be a useful measure, bootstrap methods may offer a reasonable option for inference when evaluating new predictors, as long as the added predictive capacity is large.

摘要

综合判别改善(IDI)指数是一种常用于评估标志物预测感兴趣的二项结局能力的工具。最近的报告表明,IDI 比其他指标更能敏感地识别有用的预测标志物。在本文中,作者使用模拟数据集和理论分析来研究 IDI 的统计性质。作者考虑了一种常见的情况,即风险模型拟合有和没有新候选预测因子的数据集。结果表明,用于估计 IDI 估计标准误差的已发表方法往往会低估误差。文献中提出的基于 IDI 的新生物标志物检验的 z 检验是无效的,因为即使在大样本中,检验统计量的零分布也不是标准正态分布。如果需要对标志物的增量值进行检验,作者建议基于模型的检验。对于发现 IDI 是一种有用的度量的研究人员来说,当评估新的预测因子时,自举方法可能是一种合理的推断选择,只要增加的预测能力很大。